home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

NGF accelerates corneal wound healing

  June, 23 2006 16:51
your information resource in human molecular genetics

In a study released as an Epub ahead of print by Ophthalmic Research, Cellini et al1 investigated the efficacy of nerve growth factor for healing corneal wounds after cataract surgery.

The authors administered either nerve growth factor or hyaluronic acid eye drops to 30 patients who had just undergone cataract surgery. Patients in both groups used one drop of their respective solutions every 2 hours for 2 weeks and then q.i.d. for another week.

On postoperative day 1, optical coherence tomography (OCT) showed reduced endothelial cell counts and increased temporal corneal edge thickness in both groups, compared with baseline. On postoperative day 7, patients in the nerve growth factor group had higher epithelial cell counts than patients in the hyaluronic acid group (2,511.4 ± 229.8 vs 2.490 ± 230.4). Corneal edge thickness, however, was closer to baseline in the nerve growth factor group (6.34.2 ± 22 vs 639.2 ± 24.7) than in the hyaluronic acid group (7.04.2 ± 11.8 vs 644.4 ± 31.9). By day 21, ocular coherence tomography showed complete wound healing in the eyes treated with nerve growth factor. Based on their clinical observations, the authors concluded that topical nerve growth factor accelerated corneal wound healing after cataract surgery.

Currently there are no approved drugs for use in a ocular postsurgical environment. Most ophthalmic surgeons prescribe antibiotics alone or in combination with corticosteroid to reduce inflammation. This report highlights a new way to treat the significant unment medical need of enhanced corneal wounding healing.

Message posted by: Simon Chandler

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.